Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 10;49(1):48.
doi: 10.1186/s40463-020-00446-1.

Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma

Susan Park  1   2 , Manali Vora  2 , Annemieke van Zante  3 , Joseph Humtsoe  2 , Hyun-Su Kim  2 , Sue Yom  4 , Shweta Agarwal  5 , Patrick Ha  6
Affiliations

Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma

Susan Park et al. J Otolaryngol Head Neck Surg. .

Abstract

Background: Adenoid cystic carcinoma (ACC) is the second most common malignancy of the salivary glands, accounting for ~ 1% of malignant tumors of the head and neck region and 10% of salivary gland neoplasms. Predicting the long-term outcomes of patients with ACC is still challenging, as reliable prognostic biomarkers are not available. Among salivary gland tumors, Myb overexpression is highly specific for ACC. In addition, the MYB-NF1B fusion translocation is a hallmark of ACC, and although the detection of this translocation does not appear to impact prognosis, the MYB-NF1B fusion is also implicated in MYB upregulation. Myb has recently been identified as an activator of the Wnt/β-catenin signaling pathway, and aberrant cytoplasmic expression of β-catenin has been observed in many salivary gland malignancies. In this study, we aim to analyze the impact of Myb and β-catenin expression on prognosis in ACC.

Methods: A tissue microarray constructed from archival tissue from 64 patients with ACC was stained for Myb and β-catenin; both localization and intensity were evaluated. In parallel, we abstracted demographic data, tumor characteristics, survival data, and outcomes, including local recurrence, regional recurrence, and distant metastasis from the medical record. Statistical analysis was performed.

Results: Our analysis supports that ACC patients negative for Myb by immunohistochemical methods have a higher risk of developing metastasis than patients with Myb staining (HR: 4.06, 95% CI: 1.02-14.96, p-value: 0.03). Although not statistically significant, cytoplasmic localization of β-catenin is may suggest a diminished rate of relapse-free survival (HR 2.45, 95%CI: 0.9-6.7, p = 0.08). Furthermore, Myb expression correlated with β-catenin expression, increasing 1.69 in staining intensity units with each increase in β-catenin staining intensity (p-value: 0.04).

Conclusions: Our study suggests that Myb expression is protective; Myb positive patients have diminished risk of distant metastasis. In contrast, there is a trend towards increased hazard of death in ACC patients with cytoplasmic β-catenin expression. Additional analyses will be necessary to establish Myb and β-catenin as independent protective and adverse biomarkers, respectively.

Keywords: Adenoid cystic carcinoma; Beta-catenin; Myb; Prognostic indicator.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Kokemueller H, et al. Adenoid cystic carcinoma of the head and neck--a 20 years experience. Int J Oral Maxillofac Surg. 2004;33(1):25–31. - PubMed
    1. Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg. 2004;12(2):127–132. - PubMed
    1. Li J, et al. Development and characterization of salivary adenoid cystic carcinoma cell line. Oral Oncol. 2014;50(10):991–999. - PMC - PubMed
    1. Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009;3(1):69–77. - PMC - PubMed
    1. Matsuba HM, et al. Adenoid cystic salivary gland carcinoma. A histopathologic review of treatment failure patterns. Cancer. 1986;57(3):519–524. - PubMed

MeSH terms